There is an unmet medical need for new targeted therapy opportunities in patients whose tumors harbor an NRAS mutation, occurring in 15–25% of patients with melanoma and producing the activation of Ras/Raf/MEK/ERK signaling pathway. The gene discussed is RAF1; the disease is melanoma.